Skip to main content
Funded Studies

Warren D. Hirst, PhD

Senior Director at Biogen

Location: Cambridge, MA United States

Warren D. Hirst, PhD, leads movement disorders preclinical research efforts in Biogen’s Neurodegeneration Research Unit. He is responsible for developing and driving a diverse preclinical portfolio of programs, to complement Biogen’s development efforts for its alpha-synuclein antibody, which is in Phase II trials, using multiple modalities, from antibodies and antisense oligonucleotides, in collaboration in Ionis, to gene therapy and small molecules, targeting mechanisms strongly supported by human genetics and pathology, to deliver novel disease-modifying therapeutics to patients. In his 22 years of industry experience, working for GlaxoSmithKline, Wyeth, Pfizer and now Biogen, Dr. Hirst has led teams that have discovered and advanced three molecules into clinical trials and has published over 70 peer-reviewed scientific papers. He has served on The Michael J Fox Foundation Scientific Advisory Board (2017-2019) and is currently on the Parkinson’s Disease Foundation Executive Scientific Advisory Board.

Associated Grants

  • Targeting the Body’s Circadian Clock to Improve Sleep Quality in Parkinson’s Disease


  • Co-Pathologies Drive Neuroinflammation and Progression in PD


  • Assessing Glucocerebrosidase in Sporadic Parkinson’s Disease


  • Measuring LRRK2 Levels and Activity in Sporadic Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.